CXCR4: A Promising Novel Strategy for Lung Cancer Treatment.

Lung cancer remains a major public health challenge due to high incidence and mortality. The chemokine receptor and its ligand (SDF-1) constitute a critical axis in tumor biology, influencing tumor cell proliferation, invasion, angiogenesis, and immune evasion. Aberrant expression is frequently observed in lung cancer and is closely associated with adverse prognosis, enhanced metastatic potential, and therapeutic resistance. Mechanistically, activates signaling pathways including /, /, /, and /, promoting epithelial-mesenchymal transition, stemness, and survival. The / axis also orchestrates interactions with the tumor microenvironment, facilitating chemotaxis toward -rich niches (e.g., bone marrow and brain) and modulating anti-tumor immunity via regulatory cells. Regulation of occurs at transcriptional, epigenetic, and post-transcriptional levels, with modulation by hypoxia, inflammatory signals, microRNAs, and post-translational modifications. Clinically, high expression correlates with metastasis, poor prognosis, and reduced response to certain therapies, underscoring its potential as a prognostic biomarker and therapeutic target. Therapeutic strategies targeting include small-molecule antagonists (e.g., AMD3100/plerixafor; balixafortide), anti- antibodies, and decoys, as well as imaging probes for patient selection and response monitoring (e.g., 68Ga-pentixafor PET). Preclinical and early clinical studies suggest that blockade can impair tumor growth, limit metastatic spread, and enhance chemotherapy and immunotherapy efficacy, although hematopoietic side effects and infection risk necessitate careful therapeutic design. This review synthesizes the molecular features, regulatory networks, and translational potential of in lung cancer and discusses future directions for precision therapy and biomarker-guided intervention.